These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26319488)

  • 21. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
    Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
    J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
    J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database.
    Herskovic A; Mauer E; Christos P; Nagar H
    J Thorac Oncol; 2017 Feb; 12(2):302-313. PubMed ID: 27746190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
    Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hospitalization Costs After Surgery in High-Risk Patients With Early Stage Lung Cancer.
    Sancheti MS; Chihara RK; Perez SD; Khullar OV; Fernandez FG; Pickens A; Force SD
    Ann Thorac Surg; 2018 Jan; 105(1):263-270. PubMed ID: 29174780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
    J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimum Volume Standards for Surgical Care of Early-Stage Lung Cancer: A Cost-Effectiveness Analysis.
    Subramanian MP; Yang Z; Chang SH; Willis D; Zhang J; Semenkovich TR; Heiden BT; Kozower BD; Kreisel D; Meyers BF; Patterson GA; Nava RG; Puri V
    Ann Thorac Surg; 2022 Dec; 114(6):2001-2007. PubMed ID: 35780816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of chest computed tomography after lung cancer resection: a decision analysis model.
    Kent MS; Korn P; Port JL; Lee PC; Altorki NK; Korst RJ
    Ann Thorac Surg; 2005 Oct; 80(4):1215-22; discussion 1222-3. PubMed ID: 16181843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary Resection for Second Lung Cancer After Pneumonectomy: A Population-Based Study.
    Ayub A; Rehmani SS; Al-Ayoubi AM; Raad W; Flores RM; Bhora FY
    Ann Thorac Surg; 2017 Oct; 104(4):1131-1137. PubMed ID: 28709663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer.
    Esnaola NF; Lazarides SN; Mentzer SJ; Kuntz KM
    J Clin Oncol; 2002 Jan; 20(1):263-73. PubMed ID: 11773178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer.
    Yendamuri S; Komaki RR; Correa AM; Allen P; Wynn B; Blackmon S; Hofstetter WL; Rice DC; Roth JA; Swisher SG; Vaporciyan AA; Walsh GL; Mehran RJ
    J Thorac Oncol; 2007 Nov; 2(11):1022-8. PubMed ID: 17975494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sublobar resection versus definitive radiation in patients with stage IA non-small cell lung cancer.
    Fernandez FG; Crabtree TD; Liu J; Meyers BF
    Ann Thorac Surg; 2012 Aug; 94(2):354-60; discussion 360-1. PubMed ID: 22429673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer.
    Mitera G; Swaminath A; Rudoler D; Seereeram C; Giuliani M; Leighl N; Gutierrez E; Dobrow MJ; Coyte PC; Yung T; Bezjak A; Hope AJ
    J Oncol Pract; 2014 May; 10(3):e130-6. PubMed ID: 24643574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
    J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
    JAMA Oncol; 2015 Dec; 1(9):1293-300. PubMed ID: 26313558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.